Association Between Gliflozins Use and Outcomes in Adults with Sepsis: A Multicenter Retrospective Cohort Study Among Veterans
Main finding · 90-day mortalityResult — go to the resultOdds ratio 0.591 95% CI 0.557–0.628Authors' conclusion
SGLT2i users prior to hospitalization for sepsis had reduced risk of 90-day mortality and AKI, suggesting chronic organ protection decreases the risk of organ failure when sepsis develops.
Study context
- Population
- Adult veterans with sepsis, Veterans Affairs Healthcare System National Registry, 2017–2023
- Participants
- 197,879 eligible patients
- Exposure
- Prior SGLT2i use vs non-use
- SGLT2in = 10,200
- Controlsn = 37,785reference
- Outcome
- Mortality
- Follow-up
- 90 days
Methodological detailspropensity-matched, multicentre, 1:4 matched, Sensitivity analysis using SuperLearner to estimate the propensity score and perform matching
- Propensity-matched
- Multicentre
- 1:4 matched
- Sensitivity analysis using SuperLearner to estimate the propensity score and perform matching
Main finding
90-day mortality
Odds ratio
0.591
95% CI 0.557–0.628
SGLT2i vs Controls
OR 0.591 (95% CI 0.557–0.628)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | OR (95% CI) | |
|---|---|---|
| AKI | 0.862 (0.809–0.918) | |
| MAKE-30 | 0.725 (0.683–0.771) | |
| MACE · within 90 daysNo association | 0.986 (0.931–1.044) | |
| 0.512Odds ratio (log scale) |
Hospital LOS
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| EDKASignificantly increased risk | 2.371 (2.106–2.671) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Association Between Gliflozins Use and Outcomes in Adults with Sepsis: A Multicenter Retrospective Cohort Study Among Veterans. Ann Intensive Care. Published 16 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →